Niacin (vitamin B3) has better evidence for cardiovascular benefit than statins in several important respects, and costs a fraction of the price. Yet it is rarely recommended while statins are prescribed to 40 million Americans.

Niacin's Cardiovascular Effects

Niacin has a uniquely favorable effect on the full lipid profile:

  • Raises HDL: By 15-35% — the largest HDL-raising effect of any drug or supplement
  • Lowers triglycerides: By 20-50%
  • Lowers LDL: By 10-25% (less than statins, but niacin lowers small dense LDL specifically)
  • Lowers Lp(a): By 20-30% — statins do not lower Lp(a), which is an independent cardiovascular risk factor
  • Lowers fibrinogen: Reduces clotting tendency

The Coronary Drug Project

The Coronary Drug Project (1966-1975) tested niacin in 3,908 men who had survived a heart attack. At 6 years, niacin reduced non-fatal heart attacks by 26% and stroke by 24%. At 15-year follow-up (after the trial ended), the niacin group had 11% lower all-cause mortality — suggesting a durable benefit.

The Coronary Drug Project found that niacin reduced non-fatal heart attacks by 26% and stroke by 24%. At 15-year follow-up, the niacin group had 11% lower all-cause mortality.

The AIM-HIGH and HPS2-THRIVE Trials

Two large trials — AIM-HIGH and HPS2-THRIVE — tested niacin added to statin therapy and found no additional cardiovascular benefit. These trials have been used to argue that niacin is ineffective.

However, these trials have significant limitations:

  • They tested niacin added to statins (already maximally treated patients)
  • AIM-HIGH was stopped early for futility, which may have been premature
  • HPS2-THRIVE used extended-release niacin with laropiprant (an anti-flushing drug) that may have had adverse effects

The Flushing Problem

Niacin causes flushing — a harmless but uncomfortable reddening of the skin. This is the primary reason it is not widely used. The flushing can be minimized by:

  • Taking niacin with food
  • Starting at a low dose and gradually increasing
  • Taking aspirin 30 minutes before niacin
  • Using extended-release formulations (though these have higher liver toxicity risk)

Other Natural Approaches

Other evidence-based natural approaches to cardiovascular risk reduction:

  • Omega-3 fatty acids: High-dose EPA (4g/day) reduces cardiovascular events in high-risk patients (REDUCE-IT trial)
  • Berberine: Lowers LDL and triglycerides through a mechanism similar to statins, without CoQ10 depletion
  • Red yeast rice: Contains monacolin K (identical to lovastatin) — effective but unregulated